Related Experiment Video
Updated: May 6, 2026

Techniques of Sleeve Gastrectomy and Modified Roux-en-Y Gastric Bypass in Mice
Published on: March 20, 2017
Morbi-mortality of obese patients with systemic sclerosis: A comparative study
Lucile Grange1, Benjamin Chaigne2, Marion Casadevall2
1Service de médecine interne, Centre de référence maladies systémiques autoimmunes et autoinflammatoires rares d'Île-de-France de l'Est et de l'Ouest, hôpital Cochin, Assistance publique-Hôpitaux de Paris (AP-HP), Paris, France; AP-HP-CUP, hôpital Cochin, Université Paris Cité, 75014 Paris, France; Service de médecine interne, CHU de Saint-Étienne, Saint-Étienne, France.
Introduction:
The prevalence of systemic sclerosis (SSc), as well as obesity, has significantly increased in recent decades. To address the lack of data on obese SSc patients, we conducted a retrospective comparative study to assess the prevalence, clinical characteristics, and long-term consequences of obesity in SSc patients.
Methods:
We conducted a retrospective comparative study at the Cochin University Hospital's Department of Internal Medicine (Paris) from 2000 to 2019.
Results:
Of the 911 SSc patients included, 90 (9.9%) were obese, comprising 79 females and 11 males. The median weight for obese patients was 90 [82-98] kg, compared to 60 [53-67] kg for non-obese patients, corresponding to a median body mass index of 33 [31-37] kg/m2 and 23 [20-25] kg/m2, respectively. Obese patients exhibited a higher prevalence of cardiovascular risk factors. The median modified Rodnan skin score was significantly higher in non-obese patients than in obese patients (6 [2-16] vs 3 [2-7]; P<0.05). Organ involvement did not differ significantly between obese and non-obese patients. We observed a lower number of deaths in obese SSc patients compared to non-obese SSc patients (6 [11%] vs. 26 deaths [25%], P=0.06). Analysis of 30-year Kaplan Meier survival curves did not show significant survival difference between obese and non-obese SSc patients.
Conclusions:
This study of obese ScS patients reveals that they have a higher prevalence of cardiovascular risk factors, lower mRSS, less calcinosis, and similar rates of organ damage and mortality compared to non-obese ScS patients.
Related Concept Videos
Obesity
Drug Dosing: Obese Patients
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

